These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine). Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891 [TBL] [Abstract][Full Text] [Related]
3. Replacement of chlorides with dicarboxylate ligands in anticancer active Ru(II)-DMSO compounds: a new strategy that might lead to improved activity. Bratsos I; Serli B; Zangrando E; Katsaros N; Alessio E Inorg Chem; 2007 Feb; 46(3):975-92. PubMed ID: 17257042 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and reactivity of the aquation product of the antitumor complex trans-[Ru(III)Cl4(indazole)2]-. Cebrián-Losantos B; Reisner E; Kowol CR; Roller A; Shova S; Arion VB; Keppler BK Inorg Chem; 2008 Jul; 47(14):6513-23. PubMed ID: 18553904 [TBL] [Abstract][Full Text] [Related]
12. Trans-cis-cis-[RuCl2(DMSO)2(2-amino-5-methyl-thiazole)2], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B. Mura P; Camalli M; Casini A; Gabbiani C; Messori L J Inorg Biochem; 2010 Feb; 104(2):111-7. PubMed ID: 19939460 [TBL] [Abstract][Full Text] [Related]
13. Tetranuclear coordination assemblies based on half-sandwich ruthenium(II) complexes: noncovalent binding to DNA and cytotoxicity. Linares F; Galindo MA; Galli S; Romero MA; Navarro JA; Barea E Inorg Chem; 2009 Aug; 48(15):7413-20. PubMed ID: 19586019 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure of cycloruthenated carbonyl complexes and their emission, redox and biological properties. Naresh Kumar K; Ramesh R; Liu Y J Inorg Biochem; 2006 Jan; 100(1):18-26. PubMed ID: 16310253 [TBL] [Abstract][Full Text] [Related]
15. Appraisal of the redox behaviour of the antimetastatic ruthenium(III) complex [ImH][RuCl(4)(DMSO)(Im)], NAMI-A. Ravera M; Baracco S; Cassino C; Zanello P; Osella D Dalton Trans; 2004 Aug; (15):2347-51. PubMed ID: 15278129 [TBL] [Abstract][Full Text] [Related]
16. Heteroleptic arene ruthenium complexes based on meso-substituted dipyrrins: synthesis, structure, reactivity, and electrochemical studies. Yadav M; Singh AK; Maiti B; Pandey DS Inorg Chem; 2009 Aug; 48(16):7593-603. PubMed ID: 19610658 [TBL] [Abstract][Full Text] [Related]
17. Nitric oxide binding and photodelivery based on ruthenium(II) complexes of 4-arylazo-3,5-dimethylpyrazole. Ortiz M; Torréns M; Mola JL; Ortiz PJ; Fragoso A; Díaz A; Cao R; Prados P; de Mendoza J; Otero A; Antiñolo A; Lara A Dalton Trans; 2008 Jul; (27):3559-66. PubMed ID: 18594704 [TBL] [Abstract][Full Text] [Related]
19. Ruthenium nitrosyls derived from polypyridine ligands with carboxamide or imine nitrogen donor(s): isoelectronic complexes with different NO photolability. Rose MJ; Patra AK; Alcid EA; Olmstead MM; Mascharak PK Inorg Chem; 2007 Mar; 46(6):2328-38. PubMed ID: 17315866 [TBL] [Abstract][Full Text] [Related]
20. Potential new inorganic antitumour agents from combining the anticancer traditional Chinese medicine (TCM) liriodenine with metal ions, and DNA binding studies. Chen ZF; Liu YC; Liu LM; Wang HS; Qin SH; Wang BL; Bian HD; Yang B; Fun HK; Liu HG; Liang H; Orvig C Dalton Trans; 2009 Jan; (2):262-72. PubMed ID: 19089006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]